Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer

Authors:

Abstract
No abstract available
Funding Information
  • American Association for Cancer Research
  • Lustgarten Foundation (SU2C-AACR-PCC-01-18)

This publication has 64 references indexed in Scilit: